NEW YORK (GenomeWeb News) - OPX Biotechnologies has received $3.6 million in its second round of venture financing, which was led by Mohr Davidow Ventures.
Other investors in the round included X/Seed Capital, which provided OPX’s seed financing in June 2007, and Robert Chess, who has been named OPX CEO and chairman.
Boulder, Colo.-based OPX is developing genomics technologies designed for microbial biofuel development.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.